333 related articles for article (PubMed ID: 26844286)
1. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.
Dimitrov D; Kublin JG; Ramsey S; Corey L
EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286
[TBL] [Abstract][Full Text] [Related]
2. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
3. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
Gray RT; Ghaus MH; Hoare A; Wilson DP
Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320
[TBL] [Abstract][Full Text] [Related]
4. HIV vaccine development: a subtype E-specific strategy.
Brown AE; McNeil JG
Southeast Asian J Trop Med Public Health; 1998 Jun; 29(2):377-82. PubMed ID: 9886132
[TBL] [Abstract][Full Text] [Related]
5. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
Schneider K; Kerr CC; Hoare A; Wilson DP
Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
[TBL] [Abstract][Full Text] [Related]
6. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.
Nagelkerke NJ; Hontelez JA; de Vlas SJ
Vaccine; 2011 Aug; 29(36):6079-85. PubMed ID: 21718745
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection.
Anderson RM; Swinton J; Garnett GP
Proc Biol Sci; 1995 Aug; 261(1361):147-51. PubMed ID: 7568269
[TBL] [Abstract][Full Text] [Related]
8. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
Long EF; Owens DK
Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
[TBL] [Abstract][Full Text] [Related]
11. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
Andersson KM; Stover J
Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
[TBL] [Abstract][Full Text] [Related]
12. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
14. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
15. HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
Herbeck JT; Peebles K; Edlefsen PT; Rolland M; Murphy JT; Gottlieb GS; Abernethy N; Mullins JI; Mittler JE; Goodreau SM
Vaccine; 2018 Jan; 36(4):514-520. PubMed ID: 29241646
[TBL] [Abstract][Full Text] [Related]
16. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.
Davenport MP; Ribeiro RM; Chao DL; Perelson AS
J Virol; 2004 Oct; 78(20):11340-51. PubMed ID: 15452255
[TBL] [Abstract][Full Text] [Related]
17. Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa.
Chimoyi L; Kamndaya M; Venables E; von Knorring N; Stadler J; MacPhail C; Chersich MF; Rees H; Delany-Moretlwe S
BMC Public Health; 2017 Jul; 17(Suppl 3):524. PubMed ID: 28832280
[TBL] [Abstract][Full Text] [Related]
18. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
19. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
[TBL] [Abstract][Full Text] [Related]
20. [Designing an effective AIDS vaccine: strategies and current status].
Coutsinos Z; Absi Z; Henin Y; Guillet JG; Launay O
Rev Med Interne; 2008 Aug; 29(8):632-41. PubMed ID: 18258341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
